New drug study aims to tame debilitating mast cell disease symptoms
NCT ID NCT07255638
Summary
This study is observing how well the drug avapritinib works for people with indolent systemic mastocytosis (ISM) whose symptoms aren't controlled by standard treatments. It will follow about 80 patients in Germany for up to two years as they take the drug as part of their normal care. The main goal is to see if the drug improves patients' quality of life and controls their disease symptoms in everyday settings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT SYSTEMIC MASTOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie
RECRUITINGBerlin, 10117, Germany
-
Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie
RECRUITINGTübingen, 72076, Germany
-
University Medical Center Goettingen - Georg August University of Goettingen
RECRUITINGGöttingen, 37075, Germany
-
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie
RECRUITINGDresden, 01307, Germany
Conditions
Explore the condition pages connected to this study.